MedTrace Logo

Decitabine Plus Carboplatin in the Treatment of Metastatic TNBC

NCT03295552 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2022-04-06

No results posted yet for this study

Summary

To evaluate the effect of novel DNA demethylating agents in the treatment of metastatic TNBC

Conditions

  • Breast Neoplasm

Interventions

DRUG

Decitabine

decitabine 7mg/m2, d1-d5, q3w

DRUG

Carboplatin

carboplatin AUC = 6, d6, q3w

Sponsors & Collaborators

  • Shanghai Jiao Tong University School of Medicine

    lead OTHER

Principal Investigators

  • Kunwei Shen, MD · Ruijin Hospital, Shanghai Jiaotong Univeristy School of Medicine

  • Min Lu, PHD · Ruijin Hospital, Shanghai Jiaotong Univeristy School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-15
Primary Completion
2021-06-01
Completion
2021-06-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03295552 on ClinicalTrials.gov